KR20150041783A - Ｉｇｆ1 ｒ 및 ｐｉ3ｋ에 대한 억제제의 병용 요법 - Google Patents

Ｉｇｆ1 ｒ 및 ｐｉ3ｋ에 대한 억제제의 병용 요법 Download PDF

Info

Publication number
KR20150041783A
KR20150041783A KR1020157003218A KR20157003218A KR20150041783A KR 20150041783 A KR20150041783 A KR 20150041783A KR 1020157003218 A KR1020157003218 A KR 1020157003218A KR 20157003218 A KR20157003218 A KR 20157003218A KR 20150041783 A KR20150041783 A KR 20150041783A
Authority
KR
South Korea
Prior art keywords
cancer
compound
inhibitor
antibody
igf1r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157003218A
Other languages
English (en)
Korean (ko)
Inventor
시중 후앙
말테 피터스
칼 마리아 슈마허
주 알렉산더 카오
제니퍼 로렌 갠서트
데이비드 동 은 창
Original Assignee
노파르티스 아게
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 암젠 인크 filed Critical 노파르티스 아게
Publication of KR20150041783A publication Critical patent/KR20150041783A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020157003218A 2012-07-20 2013-07-19 Ｉｇｆ1 ｒ 및 ｐｉ3ｋ에 대한 억제제의 병용 요법 Withdrawn KR20150041783A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673809P 2012-07-20 2012-07-20
US61/673,809 2012-07-20
US201361759490P 2013-02-01 2013-02-01
US61/759,490 2013-02-01
PCT/US2013/051345 WO2014015280A1 (en) 2012-07-20 2013-07-19 Combination therapy of inhibitors for igf1 r and pi3k

Publications (1)

Publication Number Publication Date
KR20150041783A true KR20150041783A (ko) 2015-04-17

Family

ID=48875809

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157003218A Withdrawn KR20150041783A (ko) 2012-07-20 2013-07-19 Ｉｇｆ1 ｒ 및 ｐｉ3ｋ에 대한 억제제의 병용 요법

Country Status (11)

Country Link
US (1) US8980259B2 (enExample)
EP (1) EP2875050A1 (enExample)
JP (1) JP2015524414A (enExample)
KR (1) KR20150041783A (enExample)
CN (1) CN104822703A (enExample)
AU (1) AU2013292298A1 (enExample)
BR (1) BR112015001212A2 (enExample)
CA (1) CA2879219A1 (enExample)
MX (1) MX2015000746A (enExample)
RU (1) RU2015105786A (enExample)
WO (1) WO2014015280A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150002623A (ko) * 2012-03-30 2015-01-07 노파르티스 아게 신경모세포종, 유잉 육종 또는 횡문근육종의 치료에 사용하기 위한 화합물
EP3104890A1 (en) * 2014-02-11 2016-12-21 Novartis AG Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
EP3294417B1 (en) * 2015-05-08 2021-10-13 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FR2714383B1 (fr) 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
EP1034188B1 (en) 1997-11-27 2006-06-07 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor (1-462)
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
EP1401476A4 (en) 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
DK1461359T3 (da) 2002-01-18 2007-07-09 Pf Medicament Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
EP2316922B1 (en) 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
KR100872204B1 (ko) 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
US7875631B2 (en) 2004-03-12 2011-01-25 Analytecon S.A. Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1 r inhibitors
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
AU2005265224B2 (en) 2004-06-21 2011-09-29 Exelixis, Inc. ACACs as modifiers of the IGF pathway and methods of use
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
CA2575808A1 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JP2008542685A (ja) 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
PT2100614E (pt) 2005-06-17 2013-12-16 Imclone Llc Antagonistas de receptor para tratamento de cancro ósseo metastático
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
EP1940796A1 (en) 2005-09-09 2008-07-09 Analytecon S.A. Isoquinolines derivatives as igf-1r inhibitors
US8044067B2 (en) 2005-09-09 2011-10-25 Analytecon S.A. Isoquinolines as IGF-1R inhibitors
CN101304996A (zh) 2005-09-16 2008-11-12 阿斯利康(瑞典)有限公司 抑制igf-1r酪氨酸激酶活性的嘧啶衍生物
WO2007095113A2 (en) 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
JP5250432B2 (ja) 2006-03-03 2013-07-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なビシクロピラゾール
SG170799A1 (en) 2006-03-28 2011-05-30 Biogen Idec Inc Anti-igf-ir antibodies and uses thereof
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
ES2430614T3 (es) * 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
US20140023661A1 (en) 2014-01-23
MX2015000746A (es) 2015-09-10
EP2875050A1 (en) 2015-05-27
CN104822703A (zh) 2015-08-05
AU2013292298A1 (en) 2015-02-05
RU2015105786A (ru) 2016-09-10
WO2014015280A1 (en) 2014-01-23
CA2879219A1 (en) 2014-01-23
JP2015524414A (ja) 2015-08-24
US8980259B2 (en) 2015-03-17
BR112015001212A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
KR20150041783A (ko) Ｉｇｆ1 ｒ 및 ｐｉ3ｋ에 대한 억제제의 병용 요법
KR102193045B1 (ko) 항-cd38 항체 및 레날리도마이드를 포함하는 조성물
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
CN115315256A (zh) 用抗tigit拮抗剂抗体治疗癌症的方法
JP2018518483A (ja) 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
KR20180027576A (ko) 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
CN113613674B (zh) 治疗小细胞肺癌的联用药物组合物
JP2011236253A (ja) 抗ｉｇｆｒ１抗体治療用組み合わせ
US20240424092A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
KR102088469B1 (ko) Mek 억제제 및 igf1r 억제제의 병용 요법
JP2022543780A (ja) 抗ガレクチン９抗体と化学療法剤の組合せがん治療
KR20230098279A (ko) Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
US20190160148A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
CN113939315B (zh) 治疗黑色素瘤的联用药物组合物
CN117715936A (zh) 用于治疗癌症的方法和组合物
CN112915202A (zh) 喹啉衍生物与pd-1单抗的药物组合
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
WO2020228657A1 (zh) 喹啉衍生物与抗体联合治疗软组织肉瘤
WO2025040080A1 (en) Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy
AU2021320130B2 (en) Treatment of CLL
US20240207398A1 (en) Methods and compositions for treating cancer
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合
TW202342527A (zh) 鱗狀非小細胞肺癌之治療

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid